Shahriar Sedghi, MD
Gastroenterology · Macon, GANPI 1689659260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 32.9% of the total.
Across 319 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$495
- Medtronic$453
- Gilead$405
- Bristol Myers Squibb$380
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$365
- plus $2K from 30 others
Across 1,837 payments — averaging $2935.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2.9M
- Janssen Research & Development, LLC$1.2M
- Takeda Pharmaceuticals U.S.A., Inc.$345K
- Pfizer$223K
- Bristol Myers Squibb$204K
- Gilead$192K
- plus $333K from 11 others
What the payments were for
- Food & beverage$6,47298%
- Education$1172%
- Gifts$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 121 | $2,174 |
| Johnson & Johnson | 32 | $495 |
| Medtronic | 9 | $453 |
| Gilead | 15 | $405 |
| Bristol Myers Squibb | 14 | $380 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $365 |
| Merck | 19 | $351 |
| Boston Scientific | 7 | $226 |
| Aroa Biosurgery Incorporated | 2 | $215 |
| Pfizer | 13 | $214 |
| Intercept Pharmaceuticals, Inc. | 10 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $186 |
| Evoke Pharma, Inc. | 5 | $174 |
| Novo Nordisk | 1 | $110 |
| QOL Medical, LLC | 3 | $80 |
| Ironwood Pharmaceuticals, Inc | 4 | $69 |
| Lilly USA, LLC | 3 | $61 |
| Amgen | 3 | $43 |
| Ferring Pharmaceuticals Inc. | 3 | $39 |
| Celltrion USA Inc. | 2 | $39 |
| Axonics, Inc. | 1 | $30 |
| UCB, Inc. | 2 | $27 |
| Nestle Healthcare Nutrition Inc. | 2 | $25 |
| Sanofi | 1 | $25 |
| Mauna Kea Technologies, Inc. | 2 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Vivus LLC | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Romark Laboratories, LC | 1 | $16 |
| Mylan Institutional Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $14 |
| CSL Behring | 1 | $13 |
| Intra-sana Laboratories | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,603 in reported general payments places this provider in the 65th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 28 | $736,467 |
| EpclusaSofosbuvir/Velpatasvir | 12 | $292,972 |
| XifaxanRifaximin | 36 | $113,377 |
| LinzessLinaclotide | 90 | $62,863 |
| InflectraInfliximab-Dyyb | 12 | $55,867 |
| CreonLipase/Protease/Amylase | 29 | $47,633 |
| ZenpepLipase/Protease/Amylase | 13 | $41,912 |
| ViberziEluxadoline | 11 | $17,832 |
| Mesalamine | 33 | $10,262 |
| Sucralfate | 83 | $5,816 |
| Ursodiol | 24 | $4,693 |
| Omeprazole | 375 | $4,547 |
| CholestyramineCholestyramine (With Sugar) | 58 | $4,260 |
| Mesalamine ErMesalamine | 22 | $3,928 |
| Famotidine | 265 | $3,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $495 | $736,46728 claims |
| GileadEpclusa | $405 | $292,97212 claims |
| AbbVieLinzess, Creon, Viberzi | $2,174 | $128,328130 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $365 | $113,37736 claims |
| PfizerInflectra | $214 | $55,86712 claims |
| Aimmune Therapeutics, Inc.Zenpep | $21 | $41,91213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Macon
- Daniel Eli PennMacon$92K
- Adam LevyMacon$44K
- Joel JudahMacon$18K
- Raymond BedgoodMacon$17K
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Satish RaoAugusta$335K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.